FDA OKs first biosimilar to prevent chemo-related infections

June 6, 2018

(HealthDay)—The first biosimilar drug to Neulasta has been approved by the U.S. Food and Drug Administration. Fulphila (pegfilgrastim) is approved for patients with non-myeloid cancer who are receiving myelosuppressive chemotherapy and have symptoms of febrile neutropenia.

A biosimilar drug, generally derived from a living organism, is approved based on that it is "highly similar" to a product that's already approved by the FDA, and that there are "no clinically meaningful differences" in safety, purity and potency, the agency said.

The most common side effects of Fulphila are pain in the bones, arms and legs. Less common but more serious include the possibility of spleen rupture, severe respiratory problems and , glomerulonephritis, leukocytosis, tumor growth, and "fatal sickle cell crises," the FDA said.

"We want to make sure that the pathway for developing biosimilar versions of approved biologics is efficient and effective, so that patients benefit from [price] competition to existing biologics once lawful intellectual property has lapsed on these products," FDA Commissioner Scott Gottlieb, M.D., said in a statement.

Fulphila is produced by Mylan, with U.S. headquarters in Canonsburg, Penn.

Explore further: 'BioSimilar' drug approved to treat certain types of anemia

More information: More Information

Related Stories

'BioSimilar' drug approved to treat certain types of anemia

May 15, 2018
(HealthDay)—Retacrit (epoetin alfa-epbx) has been approved by the U.S. Food and Drug Administration as the first "biosimilar" to the anemia drugs Epogen and Procrit.

FDA approves first biosimilar drug in US

March 8, 2015
(HealthDay)—The U.S. Food and Drug Administration has approved Zarxio (filgrastim-sndz), the first biosimilar product approved in the United States.

FDA approves biosimilar ogivri for breast, stomach cancers

December 4, 2017
(HealthDay)—Ogivri (trastuzumab-dkst) has been approved by the U.S. Food and Drug Administration as the nation's first biosimilar drug to treat certain breast and stomach cancers, the agency said Friday in a news release.

FDA approves first biosimilar drug for cancer

September 15, 2017
(HealthDay)—The first biosimilar drug to treat cancer has been approved by the U.S. Food and Drug Administration.

Novartis wins US OK for biosimilar version of Amgen's Enbrel

August 30, 2016
U.S. regulators have approved the first near-copy of Enbrel, drugmaker Amgen's pricey biologic medicine for treating rheumatoid arthritis and other immune system disorders.

FDA approves admelog for diabetes

December 12, 2017
(HealthDay)—Admelog (insulin lispro), a short-acting form of insulin, has been approved by the U.S. Food and Drug Administration to treat patients aged 3 years and older with either type of diabetes.

Recommended for you

Study: What patients really think about opioid vs non-opioid medications for chronic pain

August 14, 2018
Prescriptions of opioids for chronic pain has increased dramatically since the 1990s in spite of their known harms. Despite a shortage of scientific studies on the long-term effectiveness of opioids such as morphine, oxycodone ...

Doctors nudged by overdose letter prescribe fewer opioids

August 9, 2018
In a novel experiment, doctors got a letter from the medical examiner's office telling them of their patient's fatal overdose. The response: They started prescribing fewer opioids.

Benzodiazepine and related drug prescriptions have increased among young people in Sweden

August 7, 2018
The prevalence rate of prescriptions for benzodiazepines and benzodiazepine-related drugs (BZD)—medications used to treat anxiety, insomnia, epilepsy and other neuropsychiatric conditions—increased by 22% between 2006 ...

Unwise opioids for wisdom teeth: Study shows link to long-term use in teens and young adults

August 7, 2018
Getting wisdom teeth removed may be a rite of passage for many teens and young adults, but the opioid painkiller prescriptions that many of them receive could set them on a path to long-term opioid use, a new study finds.

Behavioral nudges lead to striking drop in prescriptions of potent antipsychotic

August 1, 2018
A study led by Columbia University's Mailman School of Public Health has found that letters targeting high prescribers of Seroquel (quetiapine), an antipsychotic with potentially harmful side effects in the elderly, significantly ...

US opioid use not declined, despite focus on abuse and awareness of risk

August 1, 2018
Use of prescription opioids in the United States has not substantially declined over the last decade, despite increased attention to opioid abuse and awareness of their risks, finds a study published by The BMJ today.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.